Page last updated: 2024-11-08

eptifibatide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID448812
CHEMBL ID1174
CHEBI ID291902
SCHEMBL ID15781
MeSH IDM0229697

Synonyms (67)

Synonym
eptifibatide ,
sch-60936
c68-22
integrelin
intrifiban
n(sup 6)-amidino-n(sup 2)-(3-mercaptopropionyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide, cyclic(1-6)-disulfide
l-cysteinamide, n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophy-l-prolyl-, cyclic (1-6)-disulfide
NCGC00167505-01
[22-carbamoyl-14-(4-guanidino-butyl)-5-(1h-indol-3-ylmethyl)-4,7,10,13,16,24-hexaoxo-docosahydro-19,20-dithia-3a,6,9,12,15,23-hexaaza-cyclopentacyclotricosen-8-yl]-acetic acid (c68-22, eptifibatide)
bdbm50092098
2-[(3s,6s,12s,20r,23s)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
CHEMBL1174 ,
chebi:291902 ,
s(1),s(6)-cyclo[n(6)-carbamimidoyl-n(2)-(3-sulfanylpropanoyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide]
[(3r,11s,17s,20s,25as)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1h-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7h-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
n(6)-amidino-n(2)-(3-mercaptopropionyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide, cyclic(1-6)-disulfide
epifibratide
epifibatide
cas-188627-80-7
dtxcid5026673
dtxsid7046673 ,
tox21_112503
unii-na8320j834
hsdb 8313
eptifibatide [inn:ban]
na8320j834 ,
eptifibatide [mart.]
eptifibatide [usan]
eptifibatide [ema epar]
eptifibatide [vandf]
eptifibatide [orange book]
l-cysteinamide, n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-, cyclic (1-->6)-disulfide
n(sup 6)-amidino-n(sup 2)-(3-mercaptopropionyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide, cyclic(1-6)-disulphide
eptifibatide [inn]
eptifibatide [who-dd]
eptifibatide [mi]
AKOS015895205
gtpl6585
eptifibatide accord (generic)
2-[(3r,11s,17s,20s,25as)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-docosahydro-1h-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
HY-B0686
SCHEMBL15781
NCGC00263524-01
tox21_112503_1
HS-2011 ,
AKOS025147403
1-[(1r)-1-phenylethyl]-1himidazole-5-carboxylic acid ethyl ester; (+)-ethyl 1-(|a-methyl-benzyl)-imidazole-5-carboxylate
l-cysteinamide,n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl)-l-lysylglycyl-l-|a-aspartyl-l-tryptophyl-l-prolyl-, cyclic (1 inverted exclamation marku6)-disulfide
Z2241982440
2-((3r,11s,17s,20s,25as)-20-((1h-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7h-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
2-((3r,11s,17s,20s,25as)-20-((1h-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-1h-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl)acetic acid
CZKPOZZJODAYPZ-LROMGURASA-N
157630-07-4
Q2295855
EX-A3111
CCG-270517
NCGC00167505-03
7h-pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1h-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3r,11s,17s,20s,25as)-
mpr-har-gly-asp-trp-pro-cys-nh2
C73610
eptifibatide (mart.)
l-cysteinamide, n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophy-l-prolyl-, cyclic(1-6)-disulfide
s(1),s(6)-cyclo(n(6)-carbamimidoyl-n(2)-(3-sulfanylpropanoyl)-l-lysylglycyl-l-alpha-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide)
b01ac16
eptifibatida
((3r,11s,17s,20s,25as)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1h-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7h-pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosin-17-yl)acetic acid
eptifibatidum

Research Excerpts

Overview

Eptifibatide (EPT) is a cyclic heptapeptide derived from a protein found in the venom of the south-eastern pygmy rattle snake used as an antiplatelet drug. It is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary intervention.

ExcerptReferenceRelevance
"Eptifibatide is an αIIbβ3 inhibitor that is currently used in the clinic. "( Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.
Brouns, SLN; Dijkgraaf, I; Hackeng, TM; Nagy, M; Suylen, DPL; van den Kerkhof, DL; Wichapong, K, 2022
)
2.4
"Eptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. "( Eptifibatide-induced acute profound thrombocytopenia: A case report.
Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F, 2022
)
3.61
"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks different pathways in platelet activation and aggregation."( Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.
Klen, J; Tonin, G, 2023
)
3.07
"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that is often used during PCI and is contraindicated in dialysis."( The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Cannon, LA; Gurm, HS; Hanzel, G; Khandelwal, A; Lalonde, TA; Schreiber, T; Seth, M; Sukul, D, 2017
)
1.44
"Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used mostly in the treatment of acute coronary syndrome (ACS). "( Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario.
Bhatia, N; Ikram, S; Sawyer, RD,
)
3.02
"Eptifibatide (EPT) is a cyclic heptapeptide derived from a protein found in the venom of the south-eastern pygmy rattle snake used as an antiplatelet drug. "( Validated High Performance Liquid Chromatographic Method for Stability Study of Eptifibatide.
Amer, EAE; Elzanfaly, ES; Galal, SAE; Zaazaa, HE, 2019
)
2.18
"Eptifibatide is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary intervention. "( Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer.
Dai, Y; Deshmukh, AJ; Ding, Z; Pothineni, NV; Watts, TE,
)
3.02
"Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. "( Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
Bardania, H; Dorkoosh, F; Faizi, M; Kobarfard, F; Naraki, M; Shojaosadati, SA; Zadeh, ME, 2017
)
2.24
"Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. "( Assessment of eptifibatide clearance by hemodialysis using an in vitro system.
Green, CA; Hudson, JQ; Jennings, LK; McNeely, EB, 2010
)
2.16
"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks the final common pathway of platelet aggregation. "( Bleeding risk and safety profile related to the use of eptifibatide: a current review.
Ionescu, C; Saab, F; Schweiger, MJ, 2012
)
2.07
"Eptifibatide is an intravenous glycoprotein IIb/IIIa inhibitor with a short half-life of ½ hours."( Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement.
Atallah, J; Cooper, C; Eltahawy, E; Palma, M; Sisk, J,
)
1.31
"Eptifibatide was found to be a strong inhibitor of both species' platelet types at concentrations greater than 0.01 microg/ml."( Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
Ahmad, S; Fareed, J; Hoppensteadt, DA; Ma, Q; Messmore, HL; Schultz, CL; Untch, B; Walenga, JM, 2002
)
1.04
"Eptifibatide is a truncated derivative of the naturally occurring rattlesnake venom protein known as barbourin. "( Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
Gilchrist, IC, 2003
)
1.96
"Eptifibatide (Integrilin) is a selective inhibitor of platelet glycoprotein (GP) IIb/IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI. "( Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Ibbotson, T; Plosker, GL, 2003
)
3.2
"Eptifibatide is a small-molecule glycoprotein (GP) IIb/IIIa receptor inhibitor."( [Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].
Senges, J; Siegler, KE; Zahn, R; Zeymer, U, 2004
)
1.96
"Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein (GP) IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway. "( Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran, MP; Keating, GM, 2005
)
3.21
"Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway. "( Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran, MP; Keating, GM, 2006
)
2.15
"Eptifibatide is a glycoprotein (GP) IIb/IIIa inhibitor used globally, but there is little information on overdose. "( Eptifibatide overdose.
Bhat, U; Naik, N; Parakh, K; Parakh, S; Rohatgi, N, 2009
)
3.24
"Eptifibatide is a small heptapeptide, which is highly selective and rapidly dissociates from its receptor after cessation of therapy."( A review of clinical trials with eptifibatide in cardiology.
Wienbergen, H; Zeymer, U, 2007
)
1.34
"Eptifibatide (INTEGRILIN) is a cyclic heptapeptide inhibitor of GP IIb-IIIa, with an active pharmacophore that is derived from the structure of barbourin, a GP IIb-IIIa inhibitor from the venom of the southeastern pigmy rattlesnake."( Clinical pharmacology of eptifibatide.
Phillips, DR; Scarborough, RM, 1997
)
1.32
"Eptifibatide (Integrilin) is a cyclic heptapeptide inhibitor that contains a modified lysine-glycine-aspartic acid sequence that recognizes the binding site of platelet GP IIb-IIIa, resulting in potent and selective inhibition of its binding to fibrinogen."( Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.
Kitt, MM; Lorenz, TJ; Macdonald, F, 1999
)
1.34
"Eptifibatide is a small, cyclic heptapeptide that has shown high specificity and high affinity for GP IIb-IIIa, a short plasma half-life, and rapid onset of antiplatelet action accompanied by a rapid reversibility of platelet inhibition once treatment is stopped."( Development of eptifibatide.
Scarborough, RM, 1999
)
1.38
"Eptifibatide (Integrilin) is a specific blocker of the glycoprotein IIb/IIIa receptor and an effective inhibitor of platelet aggregation. "( [Eptifibatide (Integrilin)].
Grande, P; Holmvang, L, 2001
)
2.66
"Eptifibatide is a potent and highly specific inhibitor of platelet receptor glycoprotein IIb/IIIa and is indicated in the treatment of acute coronary syndrome. "( Stabilization of eptifibatide by cosolvents.
Yalkowsky, SH; Zhao, L, 2001
)
2.09

Effects

ExcerptReferenceRelevance
"Eptifibatide has been studied in a broad range of ischaemic coronary conditions including percutaneous coronary intervention (PCI), ST-segment and non-ST-segment acute myocardial infarction (MI) and unstable angina."( Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
O'Shea, JC; Tcheng, JE, 2002
)
2.48

Actions

Eptifibatide patients had lower rehospitalization rates in the six months following treatment. The drug did not increase plasma levels of platelet factor 4 or beta-thromboglobulin, P-selectin exposure or platelet:leucocyte aggregate formation.

ExcerptReferenceRelevance
"Eptifibatide displays high sensitivity and excellent tolerability in healthy Chinese subjects."( Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.
Ding, Y; Hu, Y; Jiao, Z; Li, C; Li, Q; Liu, C; Liu, J; Liu, L; Wu, M; Zhang, H, 2020
)
1.5
"Eptifibatide patients had lower rehospitalization rates in the six months following treatment."( Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
Armstrong, P; Brown, R, 2003
)
1.32
"Eptifibatide did not increase plasma levels of platelet factor 4 or beta-thromboglobulin, P-selectin exposure or platelet:leucocyte aggregate formation."( Phase I study of eptifibatide in patients with sickle cell anaemia.
Ataga, KI; Lee, SP; Manganello, JM; Orringer, EP; Parise, LV; Phillips, DR; Zayed, M, 2007
)
1.4
"Eptifibatide does not suppress elevated levels of inflammatory markers in patients with non-ST-segment elevation ACS."( Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Masenko, VP; Mazaev, AA; Mazurov, AV; Naimushin, YA; Ruda, MY, 2009
)
3.24

Treatment

Eptifibatide or placebo treatment was randomly assigned in addition to standard treatment with acetylsalicylic acid and heparin. Patients were treated for a mean 20.4 (5.2) hours, with 10.1% receiving the drug before the procedure. The patients were less likely to have diabetes and renal failure and had worse angiographic characteristics.

ExcerptReferenceRelevance
"Eptifibatide pretreatment at pharmacologically relevant concentrations blocked agonist-induced increases in CD62P platelet surface density."( Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.
Chandler, AB; Earhart, AD; Hansen, J; Jennings, LK; Kueter, TJ; Speich, HE; White, MM, 2010
)
1.08
"Eptifibatide or placebo treatment was randomly assigned in addition to standard treatment with acetylsalicylic acid and heparin."( Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
Armstrong, P; Brown, R, 2003
)
2.05
"Eptifibatide patients were treated for a mean 20.4 (5.2) hours, with 10.1% receiving the drug before the procedure."( Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.
Changezi, HU; Cook, JR; Naglieri-Prescod, D; Schweiger, MJ, 2003
)
1.31
"The eptifibatide treated patients were less likely to have diabetes and renal failure and had worse angiographic characteristics."( The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction.
Assali, AR; Battler, A; Hasdai, D; Kornowski, R; Lev, EI; Rechavia, E; Shor, N; Teplisky, I, 2005
)
1.11
"Eptifibatide treatment was safe, with low rates of major bleeding (3.5%) and thrombocytopenia (1.2%); one patient developed a post-procedure compartment syndrome requiring fasciotomy."( Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial.
Rocha-Singh, KJ; Rutherford, J, 2005
)
1.31
"Eptifibatide treatment did not increase rates of major bleeding or transfusion."( Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
, 1997
)
1.27
"Eptifibatide-treated patients demonstrated nonsignificant trends toward fewer angiographic complications (10 vs. "( Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
Bachour, FA; Blankenship, JC; Cohen, DJ; Cohen, E; Iliadis, EA; Lui, HK; Mann, T; O'Shea, JC; Tasissa, G; Tcheng, JE, 2001
)
1.75
"Eptifibatide-treated patients with percutaneous coronary intervention on day 1 had the lowest rate of 30-day events (9.2%, P<0.05 vs other groups)."( Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Akkerhuis, KM; Boersma, E; Califf, RM; Deckers, JW; Harrington, RA; Karsch, K; Kleiman, NS; Lincoff, AM; Ronner, E; Simoons, ML; Topol, EJ; Vahanian, A, 2002
)
1.04
"Pretreatment with eptifibatide and symptom duration of or= 2 flow on multivariable analysis."( Administration of eptifibatide during transfer for primary PCI in patients with STEMI: effect on Pre-PCI TIMI flow and its correlation with pain-to-therapy time.
Aquilina, M; Balducelli, M; Frassineti, V; Maresta, A; Varani, E; Vecchi, G, 2009
)
1.01
"Mice treated with eptifibatide in vivo survived longer following induction of sepsis than vehicle control mice."( Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade.
Benton, AS; Freishtat, RJ; Garvin, LM; Geha, M; Hoptay, CE; Nagaraju, K; Sharron, M; Wiles, AA, 2012
)
0.7
"Treatment with eptifibatide resulted in marked clinical and hemodynamic improvement within 24 hrs."( Successful treatment of a continuous flow left ventricular assist device thrombosis with eptifibatide.
Cabrera, R; Jennings, DL; Tita, C; Wang, DD,
)
0.69
"Pretreatment with eptifibatide (with and without concomitant fibrinolytic therapy) increased reperfusion prior to PCI, setting the stage for a large ongoing trial of eptifibatide in patients with STE MI undergoing PCI."( Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
Racine, E, 2002
)
0.64

Toxicity

The antiplatelet agents ticagrelor and eptifibatide were safe in DSS colitis mice, suggesting their potential in humans suffering from ulcerative colitis, and supporting future safety studies. Low-dose ept ifibatides seemed to be safe in tandem occlusions (symptomatic intracranial hemorrhage, 2%), although asymptomatic cervical carotid artery re-occlusions still occurred in 14% of patients.

ExcerptReferenceRelevance
" A rapidly reversible peptide inhibitor of the GP IIb-IIIa receptor, eptifibatide (INTEGRILIN), has been recently evaluated in the pivotal Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT II) phase III trial, which demonstrated a favorable adverse effects profile for this agent."( Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Kleiman, NS, 1997
)
0.53
" In conclusion, the use of intravenous enoxaparin in conjunction with intravenous eptifibatide during nonemergent coronary and peripheral vascular intervention is safe and effective and eliminates the need for routine measurement of ACT during the procedure."( Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention.
Ahmed, A; Elbazour, M; Guerrero, M; Khosla, S; Kunjummen, B; Lubell, D; Manda, R; Razminia, M; Trivedi, A; Vidyarthi, V,
)
0.56
" The primary study endpoints were major adverse clinical events (MACE), defined as the in-hospital and 30-day incidence of death from any cause, Q-wave or non-Q-wave MI, repeat target vessel revascularization and/or major bleeding complications."( High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
Attia, T; Fischell, TA; Rane, S; Salman, W, 2006
)
0.64
" Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings."( Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
Cheong, BY; Díez, JG; Ferguson, JJ; Medina, HM; O'Meallie, L, 2009
)
0.35
"Eptifibatide infusion may be safe in patients with subcortical ischemic strokes."( Safety of eptifibatide for subcortical stroke progression.
Abraham, AT; Barreto, AD; Gonzales, NR; Grotta, JC; Hallevi, H; Martin-Schild, S; Savitz, SI; Shaltoni, H, 2009
)
2.2
" Its major adverse effect is bleeding."( Bleeding risk and safety profile related to the use of eptifibatide: a current review.
Ionescu, C; Saab, F; Schweiger, MJ, 2012
)
0.63
" In this pilot study, infusion of a prostacyclin analog appeared safe and has a detectable modulating effect of activated endothelium in patients with a recent STEMI."( A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST
Dridi, NP; Holmvang, L; Johansson, P; Ostrowski, SR, 2012
)
0.58
"001) reflecting the toxic effect of DXR on EC."( Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.
Bar Joseph, H; Ben Aharon, I; Farzam, N; Levi, M; Savion, N; Shalgi, R; Shenkman, B; Stemmer, SM; Tzabari, M, 2013
)
0.39
"Patients presenting with ST-segment elevation myocardial infarction (STEMI) represent a high-risk group for in-hospital adverse events and bleeding."( Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction.
Baker, NC; Escarcega, RO; Lipinski, MJ; Magalhaes, MA; Torguson, R; Waksman, R,
)
0.53
" Intention-to-treat analyses of all included patients showed no differences in serious adverse events including bleeding, use of blood products or mortality."( Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)-a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy.
Berthelsen, RE; Bestle, MH; Johansson, PI; Ostrowski, SR, 2019
)
0.79
"The antiplatelet agents ticagrelor and eptifibatide were safe in DSS colitis mice, suggesting their potential in humans suffering from ulcerative colitis, and supporting future safety studies."( Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.
Brcerevic, IA; Cikota, BM; Doder, RB; Magic, ZM; Majstorovic, IJ; Manojlovic, NS; Obradovic, SD; Perisic, NJ; Petrovic, MD; Petrovic, SS; Rancic, NK; Tarabar, DK; Vasiljevska, MM, 2020
)
1.1
"Low-dose eptifibatide seemed to be safe in tandem occlusions (symptomatic intracranial hemorrhage, 2%), although asymptomatic cervical carotid artery re-occlusions still occurred in 14% of patients."( Low-Dose Eptifibatide for Tandem Occlusion in Stroke: Safety and Carotid Artery Patency.
Brown, M; Heck, D; Janjua, R; Jost, A; Roels, C, 2021
)
1.46
" The primary outcome of this retrospective cohort study was the incidence of bleeding events defined by the global use of strategies to open occluded coronary arteries criteria, and the secondary outcomes include the transfusion requirements, inpatient major cardiac adverse events, and cost savings per patient."( Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.
Ji, CS; Roberts, RJ; Solomon, EJ; Toyoda, AY; Yun, AN, 2022
)
0.96
" The primary outcome was the success rate of no major adverse cardiovascular events (MACE)."( Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z, 2022
)
0.72
"The results of this study showed that the use of intravenous platelet glycoprotein IIb/IIIa inhibitors as a bridging strategy might be safe and effective for patients undergoing coronary stent implantation that require surgery soon after."( Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z, 2022
)
0.72

Pharmacokinetics

The present study aimed to evaluate the pharmacokinetic properties and antiplatelet aggregation activity of eptifibatide i. No clinically significant differences were found between the coadministration of UFH versus enoxaparin in platelet aggregation inhibition, t 1/2, ept ifib atide Cl, or other pharmacokinetics parameters.

ExcerptReferenceRelevance
" Pharmacodynamic effects of the platelet glycoprotein IIb/IIIa antagonist eptifibatide have been delineated in healthy subjects but not in patients with ACS."( Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Eisenberg, PR; Gretler, D; Harrington, RA; Jennings, LK; Joseph, DM; Kleiman, NS; Labinaz, M; Lincoff, AM; McDougal, MF; Potthoff, RF; Tardiff, BE; Vorchheimer, DA, 2001
)
0.81
" These results enhance our understanding of the relation between pharmacodynamic and clinical effects of eptifibatide in such patients and may have important implications for its use in percutaneous interventions."( Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Eisenberg, PR; Gretler, D; Harrington, RA; Jennings, LK; Joseph, DM; Kleiman, NS; Labinaz, M; Lincoff, AM; McDougal, MF; Potthoff, RF; Tardiff, BE; Vorchheimer, DA, 2001
)
0.79
" Pharmacokinetic modeling suggested that optimal dosing of eptifibatide would be obtained with a 180-microgram/kg bolus and a 2-microgram/kg per minute infusion followed by a second 180-microgram/kg bolus 10 minutes later."( Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Aguirre, F; Davidson, C; Gilchrist, IC; Jennings, LK; Kitt, MM; Kleiman, NS; Kosoglou, T; Lorenz, TJ; O'Shea, JC; Runyon, J; Talley, D; Tcheng, JE, 2001
)
0.79
"A novel higher-dose, double-bolus regimen of eptifibatide in coronary intervention attains and maintains >90% inhibition of platelet aggregation in >90% of patients, providing the pharmacodynamic construct for the design of the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial of adjunctive eptifibatide in coronary stent implantation."( Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Aguirre, F; Davidson, C; Gilchrist, IC; Jennings, LK; Kitt, MM; Kleiman, NS; Kosoglou, T; Lorenz, TJ; O'Shea, JC; Runyon, J; Talley, D; Tcheng, JE, 2001
)
0.81
" Dose selection for the initial trials using the three parenteral antagonists was based on in vitro and ex vivo pharmacodynamic assays conducted under different blood collection and platelet function assay conditions."( The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Jacoski, MV; Jennings, LK; White, MM, 2002
)
0.31
"This study was designed to determine whether the substitution of enoxaparin for UFH, when coadministered with eptifibatide, affects the pharmacokinetic and pharmacodynamic properties of eptifibatide."( Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
Gretler, DD, 2003
)
0.53
" The primary end point of the study was the steady-state plasma concentration of eptifibatide (Css); secondary end points included the inhibition of platelet aggregation, area under the plasma-concentration time curve, apparent volume of distribution, plasma elimination half-life (t 1/2), and total body eptifibatide clearance (Cl)."( Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
Gretler, DD, 2003
)
0.55
" In addition, no clinically significant differences were found between the coadministration of UFH versus enoxaparin in platelet aggregation inhibition, t 1/2, eptifibatide Cl, or other pharmacokinetic parameters."( Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
Gretler, DD, 2003
)
0.52
"The present study was designed to assess teh pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with various levels of creatinine clearance (CrCl), a parameter that is a more accurate indicator of renal function than serum creatinine concentration to determine the appropriate dose adjustment in patients with reduced renal function."( Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler, DD; Guerciolini, R; Williams, PJ, 2004
)
0.8
" In addition to analyses performed for each group, pharmacokinetic models were estimated and eptifibatide clearance was related to CrCl as a continuous variable by linear regression."( Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler, DD; Guerciolini, R; Williams, PJ, 2004
)
0.8
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The present study aimed to evaluate the pharmacokinetic properties and antiplatelet aggregation activity of eptifibatide in healthy Chinese subjects."( Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.
Ding, Y; Hu, Y; Jiao, Z; Li, C; Li, Q; Liu, C; Liu, J; Liu, L; Wu, M; Zhang, H, 2020
)
0.99

Compound-Compound Interactions

This study was designed to determine in a dog model of coronary thrombosis whether short-term eptifibatide (Ep) combined with low-dose plasminogen activator (rt-PA) inhibits platelet recruitment at sites of endothelial damage. Seventeen patients were random and microvascular perfusion recovered immediately after postischemic reperfusion.

ExcerptReferenceRelevance
" Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with plasminogen activator (t-PA) in an experimental model of ischemia reperfusion (I/R) in hamster cheek pouch microcirculation visualized by fluorescence microscopy."( Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.
Bertuglia, S; Giusti, A, 2002
)
0.78
"001) while t-PA combined with abiciximab or eptifibatide, was more effective and microvascular perfusion recovered immediately after postischemic reperfusion."( Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.
Bertuglia, S; Giusti, A, 2002
)
0.8
" Arterial vasoconstriction, decreased arterial RBC velocity and alterations in the endothelial barrier with increased permeability delayed the complete restoration of blood flow, while t-PA combined with inhibition of platelet aggregation speeded up the capillary perfusion after reperfusion."( Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.
Bertuglia, S; Giusti, A, 2002
)
0.54
"This study was designed to determine in a dog model of coronary thrombosis whether short-term eptifibatide (Ep) combined with low-dose plasminogen activator (rt-PA) inhibits platelet recruitment at sites of endothelial damage after normalization of platelet function."( Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
Aretz, HT; Finn, AV; Gold, HK; Hollenbach, S; Leinbach, RC; Rubenstein, MH; Virmani, R, 2004
)
0.85
" Since the pathophysiology of acute ischemic cardiac diseases involves haemostatic impairment and the therapeutic regimen includes antithrombotic drugs, we investigated the effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with platelet aggregation inhibitors (aspirin, eptifibatide and tirofiban), unfractionated heparin, low molecular weight heparin (enoxaparin) or the recombinant fibrinolytic drug (alteplase), on various haemostatic parameters in vitro."( In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O, 2006
)
0.71
" Seventeen patients were randomized to either 24 h of iloprost infusion in combination with low dose eptifibatide infusion or saline infusion+eptifibatide."( A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST
Dridi, NP; Holmvang, L; Johansson, P; Ostrowski, SR, 2012
)
0.79
" Our experience indicates that medical therapy for hemolysis and suspected LVAD thrombosis with warfarin and eptifibatide alone or in combination with argatroban or heparin appears safe and may be effective, although the episodes of recurrent hemolysis after medical management remain high."( The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices.
Abramov, D; Birks, E; Bitar, A; Lenneman, A; Massey, T; Slaughter, M; Vijayakrishnan, R, 2017
)
1.06

Bioavailability

ExcerptReferenceRelevance
" We report the use of the ClearWay® catheter to deliver IC eptifibatide to the lesion, theoretically thereby achieving higher local coronary concentrations of the eptifibatide, achieving a longer residence time and maximizing drug bioavailability at the site of the thrombus over the standard intravenous delivery mechanism and over intracoronary bolus administration via the guide catheter."( Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter.
Deibele, AJ; Michael Gibson, C, 2011
)
0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

This review provides a comprehensive evaluation of the current published literature pertaining to the use of all available GP IIb/IIIa inhibitors for thromboembolic complications. Study group 1 (10 healthy volunteers) received a DDAVP infusion to establish dose-response curves for the in vitro inhibition of platelet function.

ExcerptRelevanceReference
" Patients were randomized to placebo (n = 19) or to 1 of 4 integrelin dosing regimens (total n = 54) that were studied sequentially."( Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Harrington, RA; Joseph, D; Kleiman, NS; Kottke-Marchant, K; Lincoff, AM; Rios, G; Rose, D; Sigmon, KN; Tcheng, JE; Trainor, K, 1995
)
0.29
" Recent clinical trials suggest that, compared with heparin, direct thrombin inhibitors (such as hirudin and hirulog) offer a predictable dose-response effect on the activated partial thromboplastin time without a concomitant increase in bleeding."( Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.
Tcheng, JE, 1995
)
0.29
" Dosing strategies and treatment duration still need to be refined, especially for the competitive antagonists."( Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng, JE, 1996
)
0.29
" Further investigation to refine eptifibatide dosing during coronary intervention is warranted."( Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
, 1997
)
0.83
" Recent pharmacodynamic studies have established that more aggressive dosing of eptifibatide provides greater inhibition of ex vivo platelet aggregation and more robust antithrombotic activity."( Clinical pharmacology of eptifibatide.
Phillips, DR; Scarborough, RM, 1997
)
0.83
"VAS complications may be reduced by early sheath removal, by avoiding placement of venous sheaths and by limiting heparin dosing to avoid excessive activated clotting times."( Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Aguirre, FV; Berkowitz, SD; Blankenship, JC; Califf, RM; Gardner, LH; George, BS; Gilchrist, IC; Lincoff, AM; Mandak, JS; McIvor, M; Resar, J; Sigmon, KN; Talley, JD; Tcheng, JE; Timmis, GC; Topol, EJ; Weiner, BH, 1998
)
0.51
" Future studies will be aimed at optimizing results and improving safety through more accurate assessment of optimal dosage and duration of infusion."( [Clinical use of glycoprotein IIb/IIIa inhibitors].
Gallopin, M; Gensini, GF; Simonetti, I,
)
0.13
" These can be minimized by changes in heparin dosing and careful management of vascular sheaths."( Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Adgey, AA; Mathew, TP, 1999
)
0.3
" Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers."( Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study.
Altmann, E; Cuffie-Jackson, CA; Molhoek, PG; Neuhaus, KL; Ronner, E; Simoons, ML; van der Wieken, LR; van Kesteren, HA; Zijnen, P, 2000
)
0.62
" Dose-response curves were established on the basis of a sigmoidal Imax)-model [I=(Imax)*Cg)/(IC50g + Cg)]."( In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
Breddin, HK; Glusa, E; Graff, J; Harder, S; Just, A; Kirchmaier, CM; Klinkhardt, U; Lösche, W; Marciniak, SJ; Mascelli, MA; Westrup, D, 2001
)
0.31
", Whitehouse Station, New Jersey]) all sought to identify dosing regimens that would establish and maintain >80 % inhibition of ex vivo platelet aggregation throughout the duration of intravenous infusion."( Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos, G, 2001
)
0.31
" Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs."( Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Vernon, SM, 2001
)
0.31
" Pharmacokinetic modeling suggested that optimal dosing of eptifibatide would be obtained with a 180-microgram/kg bolus and a 2-microgram/kg per minute infusion followed by a second 180-microgram/kg bolus 10 minutes later."( Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Aguirre, F; Davidson, C; Gilchrist, IC; Jennings, LK; Kitt, MM; Kleiman, NS; Kosoglou, T; Lorenz, TJ; O'Shea, JC; Runyon, J; Talley, D; Tcheng, JE, 2001
)
0.79
" Outcomes of treatment with the platelet glycoprotein IIb/IIIa inhibitors were dependent upon proper dosing selection."( Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Califf, RM; Davidson, CJ; Gilchrist, IC; Grines, CL; Jennings, LK; Kitt, MM; Kleiman, NS; Lincoff, AM; Lorenz, TJ; O'Shea, JC; Talley, JD; Tcheng, JE, 2001
)
0.58
"5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)."( Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.
Bertolet, BD; Gupta, A; Miller, L, 2002
)
0.85
" Recent comparative pharmacodynamics studies, which used newly defined and standardized assay conditions, indicate that the platelet aggregation inhibition achieved with these dosing regimens is variable."( The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Jacoski, MV; Jennings, LK; White, MM, 2002
)
0.31
" In particular, these trials indicate: (i) the importance of selecting high-risk patients in whom substantial clinical benefit is evident, (ii) the incorporation of these agents into an early invasive strategy, thereby matching the timing of vascular injury with maximal platelet inhibition and (iii) optimal dosing to achieve the high levels of platelet inhibition that appear to be required for efficacy with these agents."( Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Bhatt, DL; Chew, DP, 2002
)
0.31
" This may have implications regarding the need for separate heparin dosing algorithms for patients undergoing PCI in the setting of different GPIIb-IIIa inhibitors."( Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.
Ball, SA; Dauerman, HL; Desourdy, MA; Furman, MI; Goldberg, RJ, 2002
)
0.58
" Positive results of trials of abciximab and eptifibatide in patients receiving PCI can be attributed to the fact that the dosage regimens of these agents in large trials consistently inhibited > 80% of platelet aggregation, particularly during the critical periprocedural period."( Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
Cheng, JW, 2002
)
0.57
" Nevertheless, none of these fibans was able to effectively block shear-induced platelet adhesion at targeted clinical dosing regimens except for abciximab."( Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X, 2002
)
0.31
" The dosage and duration of infusion of eptifibatide in this setting needs further evaluation."( Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
Agarwal, R; Bajaj, R; Bhagwat, A; Ghose, T; Gupta, RK; Haridas, KK; Kaul, U; Kumar, P; Mathews, OP; Ramesh, SS; Sapra, RR; Sethi, KK; Shahi, M; Singh, B; Soni, PK; Yadave, RD, 2002
)
0.84
" Study group 1 (10 healthy volunteers) received a DDAVP infusion to establish dose-response curves for the in vitro inhibition of platelet function by eptifibatide, abciximab, and tirofiban together with l-aspirin before and after DDAVP."( Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA, 2003
)
0.52
" Taking into account the differences in clinical efficacy of these 2 drugs in large trials investigating percutaneous coronary intervention, we hypothesized that the variable clinical effects might be related to variability in the magnitude and consistency of platelet aggregation inhibition achieved with dosing regimens of these glycoprotein IIb/IIIa inhibitors."( Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC, 2004
)
0.59
" Parameters evaluated as possible risk factors for bleeding included age, renal function, weight, heparin and glycoprotein IIb/IIIa inhibitor dosing and infusion duration, concomitant antiplatelet and/or anticoagulant medications or disease states, and baseline hemoglobin, hematocrit, or platelet counts."( Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Brouse, SD; Wiesehan, VG, 2004
)
0.32
" A 67-year-old white female received the same dosage regimen of eptifibatide for PCI with no serious adverse effects, with the treatment repeated one month later."( Eptifibatide-associated acute, profound thrombocytopenia.
Barcelona, RA; Coons, JC; Freedy, T; Hagerty, MF, 2005
)
2.01
"The importance of the relationship between clinical outcome and degree of platelet aggregation inhibition (PAI) achieved with the dosing regimens of GPIIb-IIIa inhibitors used in large trials in patients with non-ST segment elevation (NSTE) acute coronary syndromes (ACS) is increasingly appreciated."( Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.
Garza, L; Guerra, GJ; Jacoski, MV; Jennings, LK; Lui, HK; Saucedo, JF, 2004
)
0.59
"These data support the hypothesis that differences in clinical outcomes of large GPIIb-IIIa trials in patients with NSTE ACS may be related to the consistency and potency of antiplatelet effects of the dosing regimens used."( Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.
Garza, L; Guerra, GJ; Jacoski, MV; Jennings, LK; Lui, HK; Saucedo, JF, 2004
)
0.59
"Unfractionated heparin (UFH) has been considered the standard anticoagulant for patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS), yet it has limitations, including an unpredictable dose-response and intravenous administration."( Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
Goodman, S, 2005
)
0.33
" Thirty diabetic patients were randomized to receive during PCI either bivalirudin (bivalirudin group, n=15) or eptifibatide plus heparin (eptifibatide group, n=15) at standard dosing regimens."( Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.
Badimon, JJ; Karim, A; Kleiman, A; Kleiman, NS; Lev, EI; Patel, R, 2006
)
0.8
"This analysis indicates that bivalirudin with provisional GP IIb-IIIa inhibitor therapy is the most cost-effective antithrombotic treatment strategy in nonurgent PCI when its use and dosing are consistent with the REPLACE-2 trial."( Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Crouch, MA; Holdford, DA; Summers, KM, 2006
)
0.33
" Data indicate that eptifibatide, at the current recommended dosing schedule, achieves the highest level of consistent platelet inhibition compared with current doses of abciximab and tirofiban."( Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Jennings, LK, 2005
)
0.96
" The contribution of dosing to the observed sex-related differences in bleeding is unknown."( Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB, 2006
)
0.33
"Women experience more bleeding than men whether or not they are treated with GP IIb/IIIa inhibitors; however, because of frequent excessive dosing in women, up to one fourth of this sex-related risk difference in bleeding is avoidable."( Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB, 2006
)
0.33
" Several factors increase the risk of receiving excess dosing of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndrome (ACS), including older age, female gender, elevated serum creatinine, a history of diabetes mellitus, and a history of heart failure."( Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
Donovan, JL; Forrest, A; Foster, K; Gandhi, PJ; Lee, TB; Schroeder, WS; Tran, MT, 2007
)
0.7
"To assess the impact of education on physician adherence to the renal dosing recommendation for eptifibatide at 2 academic medical centers."( Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
Donovan, JL; Forrest, A; Foster, K; Gandhi, PJ; Lee, TB; Schroeder, WS; Tran, MT, 2007
)
0.92
" At site A, a 1-hour educational seminar on ACS management strategies was employed, in which 5 minutes focused on adherence of prescribers to the guideline for renal dosing recommendations for eptifibatide."( Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
Donovan, JL; Forrest, A; Foster, K; Gandhi, PJ; Lee, TB; Schroeder, WS; Tran, MT, 2007
)
0.89
" A significant increase in the adherence rate for eptifibatide dosing in patients with renal impairment was observed from 36."( Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
Donovan, JL; Forrest, A; Foster, K; Gandhi, PJ; Lee, TB; Schroeder, WS; Tran, MT, 2007
)
0.95
"This educational intervention provided by a clinical pharmacist was associated with improved prescriber adherence to dosing recommendations for eptifibatide in patients with renal impairment."( Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
Donovan, JL; Forrest, A; Foster, K; Gandhi, PJ; Lee, TB; Schroeder, WS; Tran, MT, 2007
)
0.9
" In addition, the degree of platelet inhibition achieved by this novel tirofiban dosing strategy was assessed."( High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S, 2008
)
0.35
" This dosing during PCI appears safe and compares favorably with eptifibatide bolus-only during PCI."( High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S, 2008
)
0.58
" Tirofiban and eptifibatide are renally cleared and thus must have dosage adjustment if used in patients with renal insufficiency (RI)."( Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
Anderson, JR; Riding, D,
)
0.48
"The study aimed to determine the impact on eptifibatide-associated bleeding by implementing a computerized dosing algorithm in the cardiac catheterization suite."( Impact of computerized dosing on eptifibatide-associated bleeding and mortality.
Buergler, JM; Fromm, RE; Kleiman, NS; Putney, DR, 2009
)
0.9
"Excessive dosing of eptifibatide is associated with increased bleeding rates and hospital mortality."( Impact of computerized dosing on eptifibatide-associated bleeding and mortality.
Buergler, JM; Fromm, RE; Kleiman, NS; Putney, DR, 2009
)
0.96
" There was an increase in the proportion of patients receiving recommended doses of eptifibatide dosing (74."( Impact of computerized dosing on eptifibatide-associated bleeding and mortality.
Buergler, JM; Fromm, RE; Kleiman, NS; Putney, DR, 2009
)
0.86
"In patients receiving eptifibatide in the catheterization laboratory before percutaneous coronary intervention, implementation of a computerized algorithm was associated with appropriate dosing and reduced bleeding and mortality."( Impact of computerized dosing on eptifibatide-associated bleeding and mortality.
Buergler, JM; Fromm, RE; Kleiman, NS; Putney, DR, 2009
)
0.95
"Of 8,708 patients with eCrCl and dosing data, 19% had eCrCl <50 ml/min."( Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
Armstrong, PW; Califf, RM; Giugliano, RP; Harrington, RA; Huber, K; James, SK; Melloni, C; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; White, JA, 2011
)
0.64
"KILO tested 2 novel weight-based eptifibatide dosing strategies compared with standard dosing in obese patients undergoing elective percutaneous coronary intervention (PCI)."( The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
Aguirre, FV; Alexander, JH; Arnold, A; Cohen, MG; Gretler, DD; Hassinger, N; Kandzari, DE; Stevens, SR; Vavalle, JP, 2011
)
0.65
"Sixty-seven patients weighing ≥125 kg undergoing elective PCI were randomized to 1 of 3 eptifibatide dosing regimens: standard dosing using a weight of 121 kg, actual body weight (ABW)-based dosing with no upper limit, or ideal body weight (IBW)-based dosing."( The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
Aguirre, FV; Alexander, JH; Arnold, A; Cohen, MG; Gretler, DD; Hassinger, N; Kandzari, DE; Stevens, SR; Vavalle, JP, 2011
)
0.59
"Actual body weight eptifibatide dosing leads to higher plasma concentrations and greater platelet inhibition than standard or IBW dosing in obese patients undergoing PCI."( The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
Aguirre, FV; Alexander, JH; Arnold, A; Cohen, MG; Gretler, DD; Hassinger, N; Kandzari, DE; Stevens, SR; Vavalle, JP, 2011
)
0.7
"Limited data are available regarding adverse bleeding events associated with antithrombotic agents incorrectly dosed based on renal function in patients receiving percutaneous coronary intervention (PCI)."( Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Mauro, VF; Taylor, LA, 2012
)
0.61
"To compare the incidence of bleeding during their hospital stay in patients with reduced renal function receiving incorrect doses of bivalirudin or eptifibatide to the incidence of correct doses, based on manufacturer recommendations; secondary objectives were to determine the incidence of correct dosing based on manufacturer recommendations and the incidence of TIMI (Thrombolysis in Myocardial Infarction) major bleeding."( Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Mauro, VF; Taylor, LA, 2012
)
0.81
"A chart review over a 32-month period showed that patients with reduced renal function who received either eptifibatide or bivalirudin during PCI were evaluated for correct dosing based on manufacturer recommendations, bleeding incidence according to the TIMI criteria, and extent of bleeding according to the TIMI and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) criteria."( Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Mauro, VF; Taylor, LA, 2012
)
0.82
" Eptifibatide was dosed incorrectly in 64% of the patients."( Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Mauro, VF; Taylor, LA, 2012
)
1.52
"Patients receiving incorrectly dosed eptifibatide and bivalirudin are susceptible to adverse bleeding events."( Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Mauro, VF; Taylor, LA, 2012
)
0.88
" Clinical trials evaluating its efficacy and safety in a variety of clinical settings, as well as newer dosing regimens, are discussed."( Bleeding risk and safety profile related to the use of eptifibatide: a current review.
Ionescu, C; Saab, F; Schweiger, MJ, 2012
)
0.63
"Because of the renal elimination and increased risk for bleeding events at supratherapeutic doses of eptifibatide, the manufacturer recommends dosing adjustment in patients with renal dysfunction."( Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
Eugenio, KR; Healy, MF; Murphy, PM; Speroni, KG, 2012
)
1
"To compare hypothetical renal dosing adjustments of eptifibatide using both the recommended method and several other commonly used formulas for estimating kidney function."( Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
Eugenio, KR; Healy, MF; Murphy, PM; Speroni, KG, 2012
)
1.03
" Renal dosing decisions were determined for each patient based on creatinine clearance (CrCl) estimates via the Cockcroft-Gault formula (CG) with actual body weight (ABW), ideal body weight (IBW) or adjusted weight (ADJW), and eGFR from the Modification of Diet in Renal Disease formula."( Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
Eugenio, KR; Healy, MF; Murphy, PM; Speroni, KG, 2012
)
0.78
" Therefore, correct dosing of eptifibatide is important to both patient safety and efficacy."( Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
Eugenio, KR; Healy, MF; Murphy, PM; Speroni, KG, 2012
)
1.07
" Dosing at LIC levels also induced more disaggregation than IV levels when aggregates were aged for 30 min prior to exposure."( Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
Furman, RR; Jennings, LK; Lands, LT; Moodie, GD; Speich, HE, 2013
)
0.39
" Tirofiban, in particular, fell out of favor due to inferior dosing with its original Food and Drug Administration (FDA) approved indication, but has re-emerged in the market with a high-dose bolus regimen that is considered equally as effective as the FDA approved dosing regimens of other GP IIb/IIIa inhibitors."( Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Harmon, C; King, S; Short, M, 2016
)
0.43
" This review provides a comprehensive evaluation of the current published literature pertaining to the use of all available GP IIb/IIIa inhibitors for thromboembolic complications, providing recommendations for dosing and administration of abciximab, eptifibatide, and tirofiban based on previously published rates of efficacy and intracranial hemorrhage."( Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms.
Dornbos, D; Katz, JS; Nimjee, SM; Powers, CJ; Youssef, P, 2018
)
0.66
" There is a lack of literature surrounding prolonged use of eptifibatide and optimal dosing during ECMO."( Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation.
Bohlmann, A; Gurnani, PK; March, RJ, 2018
)
1.06
" Eptifibatide was maintained at standard dosing and the heparin infusion was withheld."( Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation.
Bohlmann, A; Gurnani, PK; March, RJ, 2018
)
1.73
" Additionally, as the need for dual antiplatelet therapy due to coronary stent implantation is increasing, further studies are needed to validate optimal dosing of eptifibatide in patients at a high risk of bleeding during ECMO."( Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation.
Bohlmann, A; Gurnani, PK; March, RJ, 2018
)
1.02
" The effective inhibition of platelet aggregation (<20% platelet aggregation) occurred by 3 minutes after starting dosing to 4 hours after termination of the infusion."( Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.
Ding, Y; Hu, Y; Jiao, Z; Li, C; Li, Q; Liu, C; Liu, J; Liu, L; Wu, M; Zhang, H, 2020
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
anticoagulantAn agent that prevents blood clotting.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organic disulfideCompounds of structure RSSR in which R and R' are organic groups.
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
homodetic cyclic peptideA homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency20.87050.000811.382244.6684AID686978; AID686979
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.61750.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.32780.000229.305416,493.5996AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743215
Histone H2A.xCricetulus griseus (Chinese hamster)Potency15.55650.039147.5451146.8240AID1224845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin beta-3Homo sapiens (human)IC50 (µMol)0.22600.00010.632310.0000AID222640; AID32997
Integrin alpha-IIbHomo sapiens (human)IC50 (µMol)0.22600.00010.730910.0000AID222640; AID32997
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin beta-3Homo sapiens (human)Kd0.12000.00010.11780.6500AID1647696
Integrin alpha-V Homo sapiens (human)Kd0.12000.01090.06540.1200AID1647696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin alpha-V Homo sapiens (human)
angiogenesisIntegrin alpha-V Homo sapiens (human)
vasculogenesisIntegrin alpha-V Homo sapiens (human)
cell adhesionIntegrin alpha-V Homo sapiens (human)
cell-matrix adhesionIntegrin alpha-V Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationIntegrin alpha-V Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
positive regulation of cell population proliferationIntegrin alpha-V Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid storageIntegrin alpha-V Homo sapiens (human)
cell migrationIntegrin alpha-V Homo sapiens (human)
positive regulation of cell migrationIntegrin alpha-V Homo sapiens (human)
cell-substrate adhesionIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid transportIntegrin alpha-V Homo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-V Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin alpha-V Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin alpha-V Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin alpha-V Homo sapiens (human)
endodermal cell differentiationIntegrin alpha-V Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
apoptotic cell clearanceIntegrin alpha-V Homo sapiens (human)
positive regulation of cell adhesionIntegrin alpha-V Homo sapiens (human)
symbiont entry into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin alpha-V Homo sapiens (human)
regulation of phagocytosisIntegrin alpha-V Homo sapiens (human)
negative chemotaxisIntegrin alpha-V Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionIntegrin alpha-V Homo sapiens (human)
ERK1 and ERK2 cascadeIntegrin alpha-V Homo sapiens (human)
calcium ion transmembrane transportIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta productionIntegrin alpha-V Homo sapiens (human)
entry into host cell by a symbiont-containing vacuoleIntegrin alpha-V Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandIntegrin alpha-V Homo sapiens (human)
positive regulation of intracellular signal transductionIntegrin alpha-V Homo sapiens (human)
negative regulation of entry of bacterium into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayIntegrin alpha-V Homo sapiens (human)
cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
opsonin bindingIntegrin alpha-V Homo sapiens (human)
protein kinase C bindingIntegrin alpha-V Homo sapiens (human)
fibroblast growth factor bindingIntegrin alpha-V Homo sapiens (human)
C-X3-C chemokine bindingIntegrin alpha-V Homo sapiens (human)
insulin-like growth factor I bindingIntegrin alpha-V Homo sapiens (human)
neuregulin bindingIntegrin alpha-V Homo sapiens (human)
virus receptor activityIntegrin alpha-V Homo sapiens (human)
fibronectin bindingIntegrin alpha-V Homo sapiens (human)
protease bindingIntegrin alpha-V Homo sapiens (human)
integrin bindingIntegrin alpha-V Homo sapiens (human)
voltage-gated calcium channel activityIntegrin alpha-V Homo sapiens (human)
protein bindingIntegrin alpha-V Homo sapiens (human)
coreceptor activityIntegrin alpha-V Homo sapiens (human)
metal ion bindingIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix protein bindingIntegrin alpha-V Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytosolIntegrin alpha-V Homo sapiens (human)
plasma membraneIntegrin alpha-V Homo sapiens (human)
focal adhesionIntegrin alpha-V Homo sapiens (human)
cell surfaceIntegrin alpha-V Homo sapiens (human)
membraneIntegrin alpha-V Homo sapiens (human)
lamellipodium membraneIntegrin alpha-V Homo sapiens (human)
filopodium membraneIntegrin alpha-V Homo sapiens (human)
microvillus membraneIntegrin alpha-V Homo sapiens (human)
ruffle membraneIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta1 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta3 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta5 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta6 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta8 complexIntegrin alpha-V Homo sapiens (human)
specific granule membraneIntegrin alpha-V Homo sapiens (human)
phagocytic vesicleIntegrin alpha-V Homo sapiens (human)
extracellular exosomeIntegrin alpha-V Homo sapiens (human)
integrin complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin alpha-V Homo sapiens (human)
external side of plasma membraneIntegrin alpha-V Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222640Inhibition of human platelet aggregation collected with sodium citrate as anticoagulant2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID32997Inhibition of fibrinogen binding to alpha IIb beta-3 integrin using thrombin inhibitor PPACK as anticoagulant2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1647696Inhibition of human integrin alphavbeta3 (unknown origin)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1069974Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.
AID1372015Inhibition of GP2b/3a in rat platelet-rich plasma assessed as reduction in arachidonic acid-induced platelet aggregation at 10'-8 to 10'-5 M after 5 mins by aggregometric analysis2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (866)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's92 (10.62)18.2507
2000's532 (61.43)29.6817
2010's199 (22.98)24.3611
2020's43 (4.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.73 (24.57)
Research Supply Index7.03 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index104.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials220 (24.26%)5.53%
Reviews191 (21.06%)6.00%
Case Studies103 (11.36%)4.05%
Observational1 (0.11%)0.25%
Other392 (43.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevati [NCT00089895]Phase 39,406 participants (Actual)Interventional2004-11-01Completed
Safety and Efficacy of Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke: a Single-arm, Open-label, Multicenter Clinical Trial [NCT03844594]Phase 3220 participants (Anticipated)Interventional2019-04-06Recruiting
The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary Intervention [NCT02925923]Phase 2100 participants (Actual)Interventional2016-11-01Completed
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial [NCT05611242]Phase 3404 participants (Anticipated)Interventional2023-11-01Recruiting
Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated Trial [NCT02204852]Phase 218 participants (Actual)Interventional2014-09-30Completed
Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy [NCT01076764]Phase 313,220 participants (Actual)Interventional2010-04-30Completed
A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and [NCT00317395]Phase 23,241 participants (Actual)Interventional2006-06-30Completed
Effectiveness of Intracoronary Injection of Eptifibatide as Adjunctive Antiplatelet Therapy in Primary Coronary Intervention in Patients With ST Segment Elevation Acute Myocardial Infarction. [NCT00945308]Phase 250 participants (Anticipated)Interventional2009-08-31Not yet recruiting
Eptifibatide and ST Segment Resolution Following Primary PCI [NCT00812435]Phase 322 participants (Actual)Interventional2007-08-31Terminated
INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial [NCT00638976]Phase 391 participants (Actual)Interventional2007-11-30Completed
"The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER Stroke Trial)" [NCT00894803]Phase 2126 participants (Actual)Interventional2009-07-31Completed
Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke [NCT03735979]Phase 3514 participants (Actual)Interventional2019-10-15Active, not recruiting
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease [NCT00834899]Phase 1/Phase 213 participants (Actual)Interventional2009-01-31Terminated(stopped due to Slow accrual and no cost extension not approved by NHLBI)
Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction [NCT00426751]Phase 3429 participants (Actual)Interventional2006-10-31Completed
MEASUREMENT OF MARKERS OF PLATELET AGGREGATION AND INFLAMMATION IN ISCHEMIC STROKE SUBJECTS AFTER FIBRINOLYTIC/ANTI-THROMBOTIC USE. A PILOT STUDY. [NCT05415150]Phase 1/Phase 230 participants (Anticipated)Interventional2022-02-18Recruiting
The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone [NCT00251823]Phase 3400 participants (Anticipated)Interventional2005-07-31Completed
[NCT01863134]Phase 4140 participants (Actual)Interventional2005-01-31Completed
Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention [NCT00111566]Phase 4624 participants (Actual)Interventional2004-12-31Completed
Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin [NCT01532544]Phase 25 participants (Actual)Interventional2012-06-30Terminated(stopped due to Difficulty recruiting patients, company closed down)
Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial [NCT00250991]Phase 1/Phase 294 participants (Actual)Interventional2003-07-31Completed
Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance [NCT00289601]Phase 41,200 participants (Anticipated)Interventional2006-03-31Terminated(stopped due to Sponsor support withdrawn)
A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention [NCT01522417]Phase 2535 participants (Actual)Interventional2012-04-30Completed
IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial [NCT00719914]Phase 231 participants (Actual)Interventional2007-11-30Terminated(stopped due to Poor enrollment)
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST) [NCT00061373]Phase 218 participants (Actual)Interventional2003-05-31Completed
A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention [NCT01103440]Phase 236 participants (Actual)Interventional2007-04-30Completed
Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR) [NCT01977456]Phase 227 participants (Actual)Interventional2013-09-30Completed
Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study [NCT00370045]Phase 4200 participants Interventional2006-03-31Recruiting
A RANDOMIZED TRIAL COMPARING EPTIFIBATIDE AND PLACEBO IN PATIENTS WITH DIFFUSE CORONARY DISEASE UNDERGOING DRUG-ELUTING STENTING [NCT01454440]Phase 491 participants (Actual)Interventional2007-10-31Terminated(stopped due to The study was stopped prematurely due to slow enrolment without code breaking.)
Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention [NCT01919723]Phase 270 participants (Actual)Interventional2014-02-28Completed
Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG [NCT03383393]60 participants (Anticipated)Observational [Patient Registry]2018-01-03Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00061373 (6) [back to overview]Bleeding Events
NCT00061373 (6) [back to overview]Major Systemic Hemorrhage
NCT00061373 (6) [back to overview]MRI Selected Arm: Complete Brain Reperfusion
NCT00061373 (6) [back to overview]Non-MRI Selected Arm: Substantial Clinical Recovery (Non-MRI Arm)
NCT00061373 (6) [back to overview]Other Serious Adverse Event Related to Study Drug Administration, Including Death.
NCT00061373 (6) [back to overview]Symptomatic Intracerebral Hemorrhage (ICH)
NCT00089895 (2) [back to overview]Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.
NCT00089895 (2) [back to overview]Incidence of the Composite of Death/MI.
NCT00426751 (20) [back to overview]Number of Participants With Minor Bleedings (TIMI Classification)
NCT00426751 (20) [back to overview]Number of Participants With Major Bleedings (TIMI Classification)
NCT00426751 (20) [back to overview]Number of Participants With Complete or Partial Sum ST Resolution (STR) 60 Min After PCI
NCT00426751 (20) [back to overview]Number of Participants Who Experienced Stroke or Major Bleeding Complications
NCT00426751 (20) [back to overview]Combined Endpoint: Number of Participants With Events of Death, Re-myocardial Infarction (MI), and Urgent Target Vessel Revascularisation (UTVR)
NCT00426751 (20) [back to overview]Number of Participants With TIMI 3 Patency of Infarcted Vessels Following PCI
NCT00426751 (20) [back to overview]Number of Participants With Heart Failure Until 6 Months After PCI
NCT00426751 (20) [back to overview]Number of Participants Who Died, and/or Experienced Re-MI and UTVR (Individually Counted)
NCT00426751 (20) [back to overview]Number of Participants With Complete Sum ST Resolution (STR) 60 Minutes (Min) After Percutaneous Coronary Intervention (PCI) (Per Protocol Population)
NCT00426751 (20) [back to overview]Number of Participants With Complete Sum ST Resolution (STR) 60 Min After Percutaneous Coronary Intervention (PCI) (Intent-to-Treat Population)
NCT00426751 (20) [back to overview]Number of Participants With Complete Single Lead ST Resolution (STR) 60 Min After PCI
NCT00426751 (20) [back to overview]Number of Participants Who Died and or Experienced Re-MI Until 6 Months After PCI
NCT00426751 (20) [back to overview]Mean Change From Baseline in Single Lead ST Resolution (STR) 60 Min After PCI
NCT00426751 (20) [back to overview]Mean Change From Baseline in the Sum ST Resolution (STR) Before PCI
NCT00426751 (20) [back to overview]Mean Change From Baseline in the Sum ST Resolution 60 Min After PCI
NCT00426751 (20) [back to overview]Mean Duration of Stay in the Ward
NCT00426751 (20) [back to overview]Mean Number of Corrected TIMI Frame Counts (cTIMI) Following PCI
NCT00426751 (20) [back to overview]Mean Maximum ST Deviation Existing (Max STE) 60 Min After PCI
NCT00426751 (20) [back to overview]Number of Participants With the Indicated Myocardial Blush Grade (TIMI Myocardial Perfusion Grade [TMPG]) After PCI
NCT00426751 (20) [back to overview]Number of Participants With the Indicated Patency of Infarcted Vessels According to Thrombolysis in Myocardial Infarction (TIMI) Classification Before PCI
NCT00834899 (4) [back to overview]1) Major Bleeding Episodes
NCT00834899 (4) [back to overview]Change in Platelet Count
NCT00834899 (4) [back to overview]Effect of Eptifibatide on Duration of Acute Pain Episodes
NCT00834899 (4) [back to overview]Effect of Eptifibatide on Duration of Hospitalization
NCT00894803 (15) [back to overview]NIH Stroke Scale Score (NIHSS) ≤ 2
NCT00894803 (15) [back to overview]NIH Stroke Scale Score (NIHSS) ≤ 5
NCT00894803 (15) [back to overview]NIH Stroke Scale Score (NIHSS) ≤2 at 90 Days
NCT00894803 (15) [back to overview]Serious Systemic Bleeding
NCT00894803 (15) [back to overview]Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset
NCT00894803 (15) [back to overview]Death Within 7 Days of Treatment Onset
NCT00894803 (15) [back to overview]Symptomatic Intracranial Hemorrhage (sICH) Within 7 Days of Treatment Onset
NCT00894803 (15) [back to overview]Asymptomatic Intracranial Hemorrhage (asICH) Within 7 Days of Treatment Onset
NCT00894803 (15) [back to overview]Barthel Index ≥ 95
NCT00894803 (15) [back to overview]Death Due to Stroke Within 7 Days of Treatment Onset
NCT00894803 (15) [back to overview]Death Due to Stroke Within 90 Days of Treatment Onset
NCT00894803 (15) [back to overview]Death Within 90 Days of Treatment Onset
NCT00894803 (15) [back to overview]Glasgow Outcome Scale (GOS) of 1
NCT00894803 (15) [back to overview]Modified Rankin Scale (mRS) of 0-1
NCT00894803 (15) [back to overview]Modified Rankin Scale (mRS) Score <1 or Return to mRS Baseline
NCT01103440 (2) [back to overview]Number of Participants With Elevation of Cardiac Enzyme
NCT01103440 (2) [back to overview]Number of Participants With Major Adverse Cardiac Event (MACE)
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (≥ 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding
NCT01522417 (5) [back to overview]Individual Components of Death, Urgent Target Revascularization or Major Bleeding
NCT01522417 (5) [back to overview]Individual Components of Periprocedural Myonecrosis
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization
NCT01863134 (1) [back to overview]Major Adverse Cardiac and Cerebrovascular Events (MACCE)
NCT01919723 (4) [back to overview]Bleeding Complications
NCT01919723 (4) [back to overview]Change in Percent Inhibition of Platelet Aggregation (%IPA)
NCT01919723 (4) [back to overview]Periprocedural Myocardial Infarction (PMI)
NCT01919723 (4) [back to overview]High On-treatment Platelet Reactivity (HPR)
NCT01977456 (4) [back to overview]The Number of Participants With Good Outcomes According to the Modified Rankin Score.
NCT01977456 (4) [back to overview]The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).
NCT01977456 (4) [back to overview]The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).
NCT01977456 (4) [back to overview]The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).
NCT02925923 (12) [back to overview]Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]Number of Participants With a Periprocedural Myocardial Infarction and Injury (PMI)
NCT02925923 (12) [back to overview]Heparin Dose, Unit/Kg
NCT02925923 (12) [back to overview]Activated Clotting Time (ACT), Seconds
NCT02925923 (12) [back to overview]Platelet Aggregation Levels
NCT02925923 (12) [back to overview]Number of Patients With Negative Clinical Outcomes
NCT02925923 (12) [back to overview]Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR)
NCT02925923 (12) [back to overview]Change in Hemoglobin Levels (g/dL)
NCT02925923 (12) [back to overview]Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]A Change in Hematocrit Levels

Bleeding Events

Bleeding events of any type, severity and at any time throughout the 30-day trial period. (NCT00061373)
Timeframe: 2 hr, 24 hr, 72 hr, 5 days, 30 days from start of study drugs

Interventionparticipants (Number)
MRI- Selected Patients8
Non-MRI Selected Patients1

[back to top]

Major Systemic Hemorrhage

Major systemic hemorrhage is defined bleeding associated with an adjusted decrease in hemoglobin of greater than 5 grams per diluent (g/dL), or and adjusted decrease in hematocrit greater than or equal to 15 percentage points or bleeding causing persistent or significant disability or incapacity such as hemorrhage in the eye. (NCT00061373)
Timeframe: From the start of study drugs and prior to 72-hour head CT

Interventionparticipants (Number)
MRI- Selected Patients0
Non-MRI Selected Patients0

[back to top]

MRI Selected Arm: Complete Brain Reperfusion

This is the primary response outcome measure for patients in the MRI arm. A positive response is measured by evidence of complete reperfusion (or restoration of blood flow)on the perfusion weighted images (PWI) and mean transit time (MTT) maps of MRIs at 2 hours and sustained at 24 hours. (NCT00061373)
Timeframe: up to 24 hours from the start of study drugs

Interventionparticipants (Number)
MRI- Selected Patients0

[back to top]

Non-MRI Selected Arm: Substantial Clinical Recovery (Non-MRI Arm)

"This is the primary response outcome measure for subjects in the non-MRI arm. A positive response is measured by a 7 point or more improvement in the NIHSS or for those with less than 7 points at baseline,complete resolution of stroke symptoms.~The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute stroke on the levels of consciousness, language, neglect, visual-field loss, extra ocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patient's ability to answer questions and perform activities. Ratings for each of the 15 items are scored. Patients who have a score of 0 are considered to have normal examination. Patients with a score of 40 have the most severe stroke symptoms." (NCT00061373)
Timeframe: up to 24 hours from the start of study drugs

Interventionparticipants (Number)
MRI- Selected Patients3
Non-MRI Selected Patients2

[back to top] [back to top]

Symptomatic Intracerebral Hemorrhage (ICH)

"This is a primary safety outcome or toxicity measure for all subjects.~Symptomatic ICH is defined as the presence of two conditions: evidence of hemorrhage on the 72-hour head CT and an increase in the NIHSS score of 4 or more points from the prior examination. Hemorrhage classifications are according to European Cooperative Acute Stroke Study (ECASS).~The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute stroke on the levels of consciousness, language, neglect, visual-field loss, extra ocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patient's ability to answer questions and perform activities. Ratings for each of the 15 items are scored. Patients who have a score of 0 are considered to have normal examination. Patients with a score of 40 have the most severe stroke symptoms." (NCT00061373)
Timeframe: From the start of study drugs and prior to the 72-hour safety head CT

Interventionparticipants (Number)
MRI- Selected Patients1
Non-MRI Selected Patients1

[back to top]

Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.

(NCT00089895)
Timeframe: 96 hours after randomization

Interventionpercentage of participants (Number)
Eptifibatide9.3
Placebo10.0

[back to top]

Incidence of the Composite of Death/MI.

(NCT00089895)
Timeframe: 30 days after randomization

Interventionpercentage of participants (Number)
Eptifibatide11.2
Placebo12.3

[back to top]

Number of Participants With Minor Bleedings (TIMI Classification)

The number of participants with minor bleedings (according to TIMI classification: clinically overt bleeding [e.g., gross haematuria or haematemesis) associated with a drop in haematocrit of ≥ 9% or a drop in haemoglobin of ≥ 3 g/dL) within the specified timeframe was measured. (NCT00426751)
Timeframe: Day 7 or hospital discharge; Day 30 after index-MI

,
Interventionparticipants (Number)
Minor bleedings (TIMI classification) until day 7Minor bleedings (TIMI classification) until day 30
Abciximab1212
Eptifibatide1919

[back to top]

Number of Participants With Major Bleedings (TIMI Classification)

Number of participants with major bleedings (according to TIMI classification: intracranial haemorrhage, spontaneous bleeding, bleeding at any instrumented site, retroperitoneal bleeding, or clinically significant overt haemorrhage associated with a drop in haematocrit of ≥ 15% or a drop in haemoglobin of ≥ 5 g/dL) within the specified timeframe was measured. (NCT00426751)
Timeframe: Day 7 or hospital discharge; Day 30 after index-MI

,
Interventionparticipants (Number)
Major bleedings (TIMI classification) until day 7Major bleedings (TIMI classification) until day 30
Abciximab01
Eptifibatide66

[back to top]

Number of Participants With Complete or Partial Sum ST Resolution (STR) 60 Min After PCI

Sum STR was calculated as the difference between baseline (ECGI) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline (Complete: ≥ 70% resolution; Partial: ≥ 30% and < 70% resolution; None: < 30% resolution). (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

,
Interventionparticipants (Number)
Complete sum STR( ≥70%)Complete or partial sum STR (≥30%)Partial sum STR (≥30% and <70%)No sum STR (<30%)
Abciximab1031545142
Eptifibatide1241805634

[back to top]

Number of Participants Who Experienced Stroke or Major Bleeding Complications

Number of participants who experienced stroke (hemorrhagic, non-hemorrhagic) or major bleedings (TIMI class: intracranial haemorrhage, spontaneous bleeding, bleeding at any instrumented site, retroperitoneal bleeding, or clinically significant overt haemorrhage associated with a drop in haematocrit of ≥ 15% or a drop in haemoglobin of ≥ 5 g/dL). (NCT00426751)
Timeframe: Day 7 or hospital discharge; Day 30 after index-MI

,
Interventionparticipants (Number)
Stroke or major bleeding until day 7 or dischargeStroke or major bleeding until day 30
Abciximab12
Eptifibatide66

[back to top]

Combined Endpoint: Number of Participants With Events of Death, Re-myocardial Infarction (MI), and Urgent Target Vessel Revascularisation (UTVR)

The number of participants who died, experienced re-MI, or experienced UTVR (necessity of re-PCI of the target vessel or coronary artery bypass graft [CABG] because of recurrent ischaemic angina within 30 days after PCI) within the specified timeframe was measured. (NCT00426751)
Timeframe: Day 7 or hospital discharge; Day 30 after index-MI

,
Interventionparticipants (Number)
Death, re-MI, or UTVR until day 7 or dischargeDeath, re-MI, or UTVR until day 30
Abciximab1417
Eptifibatide1217

[back to top]

Number of Participants With TIMI 3 Patency of Infarcted Vessels Following PCI

The number of participants with TIMI grade 3 (complete perfusion) patency of the infarcted vessels following PCI, as assessed by core angiography lab, was measured. (NCT00426751)
Timeframe: after PCI

Interventionparticipants (Number)
Eptifibatide145
Abciximab137

[back to top]

Number of Participants With Heart Failure Until 6 Months After PCI

The number of participants with heart failure within 6 month after PCI was measured. (NCT00426751)
Timeframe: until 6 Months (Day 180) after index-MI

Interventionparticipants (Number)
Eptifibatide23
Abciximab22

[back to top]

Number of Participants Who Died, and/or Experienced Re-MI and UTVR (Individually Counted)

The number of participants who died, and/or experienced re-MI or UTVR (individually counted) within the specified timeframe was measured. (NCT00426751)
Timeframe: Day 7 or hospital discharge; Day 30 after index-MI

,
Interventionparticipants (Number)
Deaths until day 7 or dischargeDeaths until day 30Re-MI until day 7 or dischargeRe-MI until day 30UTVR until day 7 or dischargeUTVR until day 30
Abciximab7735810
Eptifibatide8130055

[back to top]

Number of Participants With Complete Sum ST Resolution (STR) 60 Minutes (Min) After Percutaneous Coronary Intervention (PCI) (Per Protocol Population)

Sum STR was calculated as the difference between baseline (ECG I) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with the infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline value (Complete: ≥ 70% resolution). (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

Interventionparticipants (Number)
Eptifibatide71
Abciximab65

[back to top]

Number of Participants With Complete Sum ST Resolution (STR) 60 Min After Percutaneous Coronary Intervention (PCI) (Intent-to-Treat Population)

Sum STR was calculated as the difference between baseline (ECG I) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with the infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline value (Complete: ≥ 70% resolution). (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

Interventionparticipants (Number)
Eptifibatide124
Abciximab103

[back to top]

Number of Participants With Complete Single Lead ST Resolution (STR) 60 Min After PCI

Single lead STR is calculated as the difference (as a percentage) between baseline (ECG I) and ECG III of either the ST elevation on one of the leads (II, III, aVF, V5, and V6) or the ST depression of one of the precordial leads (V1- V4), whichever lead showed the largest deviation either at baseline or at ECG III, respectively (Complete: ≥ 70%; Partial: ≥ 30% and <70%). (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

Interventionparticipants (Number)
Eptifibatide105
Abciximab82

[back to top]

Number of Participants Who Died and or Experienced Re-MI Until 6 Months After PCI

The number of participants who died and/or experienced re-MI within 6 month after PCI was measured. (NCT00426751)
Timeframe: until 6 Month (Day 180) after index-MI

Interventionparticipants (Number)
Eptifibatide15
Abciximab15

[back to top]

Mean Change From Baseline in Single Lead ST Resolution (STR) 60 Min After PCI

Single lead STR is calculated as the difference between baseline (ECG I) and ECG III of either the ST elevation on one of the leads (II, III, aVF, V5, and V6) or the ST depression of one of the precordial leads (V1 -V4), whichever lead showed the largest deviation either at baseline or at follow-up, respectively. STR was expressed as a percentage from baseline. (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

Interventionpercent change (Mean)
Eptifibatide70.2
Abciximab64.0

[back to top]

Mean Change From Baseline in the Sum ST Resolution (STR) Before PCI

Mean sum STR was calculated as the difference between baseline (ECGI) and ECG II: the mean of the sum of ST elevation resolution from all ECG leads associated with infarct location. ST resolution was expressed as a percentage from baseline. (NCT00426751)
Timeframe: Baseline (ECG I) and immediately prior to PCI (ECG II)

Interventionpercent change (Mean)
Eptifibatide25.9
Abciximab21.2

[back to top]

Mean Change From Baseline in the Sum ST Resolution 60 Min After PCI

Sum STR was calculated as the difference between baseline (ECGI) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline. (NCT00426751)
Timeframe: Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)

Interventionpercent change (Mean)
Eptifibatide71.6
Abciximab66.3

[back to top]

Mean Duration of Stay in the Ward

Costs were measured as the duration of stay in the ward (outpatient, normal ward, and intensive care unit) within the specified timeframe was measured. (NCT00426751)
Timeframe: until 6 months after index-MI

Interventiondays (Mean)
Eptifibatide8.0
Abciximab9.7

[back to top]

Mean Number of Corrected TIMI Frame Counts (cTIMI) Following PCI

cTIMI frame counts (number of cineframes needed for dye to reach standardized distal landmarks in a coronary vessel; objective index of coronary blood flow) following PCI, as assessed by core angiography lab. (NCT00426751)
Timeframe: after PCI

Interventionnumber of frame counts (Mean)
Eptifibatide25.3
Abciximab23.6

[back to top]

Mean Maximum ST Deviation Existing (Max STE) 60 Min After PCI

Max STE is measured similarly to single-lead STR, but was not compared with the ST deviation on the baseline ECG I. It was the existing ST deviation on the single ECG lead of maximum ST deviation present at 60 minutes after the PCI (ECG III). (NCT00426751)
Timeframe: 60 min +/- 15 min after PCI (ECG III)

Interventionmillimeters (mm) (Mean)
Eptifibatide1.1
Abciximab1.4

[back to top]

Number of Participants With the Indicated Myocardial Blush Grade (TIMI Myocardial Perfusion Grade [TMPG]) After PCI

The number of participants with the indicated myocardial blush grade (TMPG), used to assess the myocardial reperfusion in the infarcted myocardium following PCI (as assessed by the core angiography laboratory), was measured. Blush grades: 0 = failure of dye to enter the microvasculature; 1 = dye slowly enters but fails to exit the microvasculature; 2 = delayed entry and exit of dye from the microvasculature; 3: normal entry and exit of dye from the microvasculature. Blush that is of only mild intensity throughout the washout phase but fades minimally is also classified as grade 3. (NCT00426751)
Timeframe: after PCI

,
Interventionparticipants (Number)
Myocardial blush Grade 3Myocardial blush Grade 2Myocardial blush Grade 1Myocardial blush Grade 0Not assessable
Abciximab540961134
Eptifibatide640981338

[back to top]

Number of Participants With the Indicated Patency of Infarcted Vessels According to Thrombolysis in Myocardial Infarction (TIMI) Classification Before PCI

Number of participants with the respective patency of the infarcted vessels was evaluated by TIMI (Thrombolysis In Myocardial Infarction) flow grades (Grade 0 = No perfusion, Grade 1 = Penetration with minimal perfusion, Grade 2 = Partial perfusion, Grade 3 = Complete perfusion), as assessed by core angiography lab. (NCT00426751)
Timeframe: immediately before PCI

,
Interventionparticipants (Number)
TIMI 3 patency before PCITIMI 2/3 patency before PCITIMI 0/1 patency before PCI
Abciximab5967123
Eptifibatide7485117

[back to top]

1) Major Bleeding Episodes

Major bleeding episodes are defined as any episode, such as gastrointestinal bleeding or intracranial bleed that typically leads to hospitalization or other prolonged bleeding requiring a blood transfusion (NCT00834899)
Timeframe: Up to 35 days

Interventionparticipants (Number)
Eptifibatide0
Placebo0

[back to top]

Change in Platelet Count

Change in platelet counts occurring anytime from randomization up to day 35 (final follow-up visit). (NCT00834899)
Timeframe: Up to 35 days

Interventionx 10^9/L (Median)
Eptifibatide97
Placebo-5

[back to top]

Effect of Eptifibatide on Duration of Acute Pain Episodes

"The duration of the pain episode will be defined as the time from randomization to termination of the pain episode. The pain episode will be considered terminated when the patient states that the crisis is resolved (defined as being ready to go home on oral analgesics) or all of the following criteria are met:~Pain relief (pain scores ≤ 40) maintained for at least 2 consecutive readings (assessed using a visual analog scale with measurements from 0 - 100, where 0 is no pain and 100 is worst imaginable pain).~No parenteral analgesics have been administered for at least 12 hours.~Ability to walk normally (unless he/she was unable to walk for some other reason prior to the crisis onset)." (NCT00834899)
Timeframe: Up to 7 days

InterventionDays (Median)
Eptifibatide3.0
Placebo3.0

[back to top]

Effect of Eptifibatide on Duration of Hospitalization

The duration of hospitalization will be defined as the period from randomization to the time an order for discharge from the hospital is written. (NCT00834899)
Timeframe: Up to 7 days

InterventionDays (Median)
Eptifibatide3.0
Placebo3.0

[back to top]

NIH Stroke Scale Score (NIHSS) ≤ 2

"Study subjects with an NIH stroke scale score of ≤ 2 at 24 hours from treatment onset, those dead (n=1) or sedated and unable to be evaluated by the NIHSS were assigned the bad outcome (n=5).~The NIH stroke scale score is scale based on 15 items individually scored between 0-2, 0-3 or 0-4 depending upon the item. The individual items are summed to produce a score between 0 and 42, where 0 indicates no deficit and 42 indicates death." (NCT00894803)
Timeframe: Within 24 hours of treatment onset

,
Interventionparticipants (Number)
NIHSS ≤ 2NIHSS > 2
Rt-PA and Eptifibatide2774
Rt-PA Only520

[back to top]

NIH Stroke Scale Score (NIHSS) ≤ 5

"Study subjects with an NIH stroke scale score of ≤ 5 at 2 hours from treatment onset, those sedated and unable to be evaluated by the NIHSS were assigned the bad outcome (n=1).~The NIH stroke scale score is scale based on 15 items individually scored between 0-2, 0-3 or 0-4 depending upon the item. The individual items are summed to produce a score between 0 and 42, where 0 indicates no deficit and 42 indicates death." (NCT00894803)
Timeframe: Within 2 hours of treatment onset

,
Interventionparticipants (Number)
NIHSS ≤ 5NIHSS > 5
Rt-PA and Eptifibatide3566
Rt-PA Only619

[back to top]

NIH Stroke Scale Score (NIHSS) ≤2 at 90 Days

"Study subjects with an NIH stroke scale score ≤ 2 points at 90 days from treatment onset compared to baseline value, those dead or unable to be evaluated by the NIHSS were assigned the bad outcome.~The NIH stroke scale score is scale based on 15 items individually scored between 0-2, 0-3 or 0-4 depending upon the item. The individual items are summed to produce a score between 0 and 42, where 0 indicates no deficit and 42 indicates death." (NCT00894803)
Timeframe: 90 days from treatment onset

,
Interventionparticipants (Number)
NIHSS ≤ 2NIHSS > 2
Rt-PA and Eptifibatide4556
Rt-PA Only1114

[back to top]

Serious Systemic Bleeding

Incidence of serious systemic bleeding defined as requiring transfusion of 2 or more units of packed red blood cells. (NCT00894803)
Timeframe: Within 7 days of treatment onset

,
Interventionparticipants (Number)
Serious systemic bleedingNo Serious systemic bleeding
Rt-PA and Eptifibatide1100
Rt-PA Only025

[back to top]

Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset

Primary safety outcome measure - Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator (NCT00894803)
Timeframe: Within 36 hours of initiation of therapy

,
Interventionparticipants (Number)
sICH within 36 hours of treatment onsetNo sICH within 36 hours of treatment onset
Rt-PA and Eptifibatide299
Rt-PA Only322

[back to top]

Death Within 7 Days of Treatment Onset

Death due to any cause within 7 days of treatment onset (NCT00894803)
Timeframe: Within 7 days of treatment onset

,
Interventionparticipants (Number)
Death within 7 days of treatment onsetNo death within 7 days of treatment onset
Rt-PA and Eptifibatide1289
Rt-PA Only322

[back to top]

Symptomatic Intracranial Hemorrhage (sICH) Within 7 Days of Treatment Onset

Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator (NCT00894803)
Timeframe: Within 7 days of treatment onset

,
Interventionparticipants (Number)
sICH within 7 days of treatment onsetNo sICH within 7 days of treatment onset
Rt-PA and Eptifibatide299
Rt-PA Only322

[back to top]

Asymptomatic Intracranial Hemorrhage (asICH) Within 7 Days of Treatment Onset

Any ICH observed on CT by the study site neuroradiologist and the independent study neuroradiologist; the central reader. The ICH would not be related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH,where judgment of significant neurological decline was made by the local clinical investigator. A third independent reader will make the final determination if there is disagreement between the treating investigator and the central reader (NCT00894803)
Timeframe: Within 7 days of treatment onset

,
Interventionparticipants (Number)
asICH within 7 days of treatment onsetNo asICH within 7 days of treatment onset
Rt-PA and Eptifibatide1685
Rt-PA Only322

[back to top]

Barthel Index ≥ 95

"Barthel index score of ≥ 95. The scale was performed by a study site investigator not directly involved with acute treatment of the patient. Study subjects dead at 90 days and those lost to follow-up were assigned the bad outcome.~The Barthel index is a score comprised of 10 individual items. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The individual items are summed to produce a total score between 0 and 100; where 0 is inferior performance and 100 is optimal. A score of ≥ 95 is usually considered excellent." (NCT00894803)
Timeframe: 90 days from treatment onset

,
Interventionparticipants (Number)
Barthel Index ≥ 95Barthel Index < 95
Rt-PA and Eptifibatide5546
Rt-PA Only1114

[back to top]

Death Due to Stroke Within 7 Days of Treatment Onset

Death due to stroke within 7 days of treatment onset. Classified by blinded clinical investigators (NCT00894803)
Timeframe: Within 7 days of treatment onset

,
Interventionparticipants (Number)
Death due to stroke within 7 days of treatment onsNo Death due to stroke within 7 days of treatment
Rt-PA and Eptifibatide1289
Rt-PA Only322

[back to top]

Death Due to Stroke Within 90 Days of Treatment Onset

Death due to stroke within 90 days of treatment onset. Classified by blinded clinical investigators (NCT00894803)
Timeframe: Within 90 days of treatment onset

,
Interventionparticipants (Number)
Death due to stroke within 90 days of treatment onNo Death due to stroke within 90 days of treatment
Rt-PA and Eptifibatide1586
Rt-PA Only421

[back to top]

Death Within 90 Days of Treatment Onset

Death due to any cause within 90 days of treatment onset (NCT00894803)
Timeframe: Within 90 days of treatment onset

,
Interventionparticipants (Number)
Death within 90 days of treatment onsetNo death within 90 days of treatment onset
Rt-PA and Eptifibatide2081
Rt-PA Only421

[back to top]

Glasgow Outcome Scale (GOS) of 1

"Glasgow outcome scale score of 1 versus greater than 1. The scale was performed by a study site investigator not directly involved with acute treatment of the patient. Study subjects dead at 90 days and those lost to follow-up were assigned the bad outcome.~The Glasgow Outcome Scale is scored; 1=good recovery, 2=moderately disabled, 3=severely disabled, 4=vegetative survival, 5=dead." (NCT00894803)
Timeframe: 90 days from treatment onset

,
Interventionparticipants (Number)
GOS =1GOS > 1
Rt-PA and Eptifibatide5249
Rt-PA Only1015

[back to top]

Modified Rankin Scale (mRS) of 0-1

"Modified Rankin Scale of 0 or 1. The scale was performed by a study site investigator not directly involved with acute treatment of the patient. Study subjects dead at 90 days were given a value of '6', and assigned the bad outcome. Also those lost to follow-up were assigned the bad outcome.~The Modified Rankin Score (mRS) is a 6 point ordinal scale, measuring functional status. 0 (no symptoms at all), 5 (severe disability; bedridden, incontinent, and requiring constant nursing care)." (NCT00894803)
Timeframe: 90 days from treatment onset

,
Interventionparticipants (Number)
mRS of 0-1mRS > 1
Rt-PA and Eptifibatide4457
Rt-PA Only619

[back to top]

Modified Rankin Scale (mRS) Score <1 or Return to mRS Baseline

"Primary efficacy outcome measure - Modified Rankin Scale of 0 or 1 or return to the pre-stroke value at baseline or better. The scale was performed by a study site investigator not directly involved with acute treatment of the patient. Study subjects dead at 90 days were given a value of '6', and assigned the bad outcome. Also those lost to follow-up were assigned the bad outcome.~The Modified Rankin Score (mRS) is a 6 point ordinal scale, measuring functional status. 0 (no symptoms at all), 5 (severe disability; bedridden, incontinent, and requiring constant nursing care)." (NCT00894803)
Timeframe: 90 days from treatment onset

,
Interventionparticipants (Number)
mRS of 0-1 or return to baselinemRS >1 and > baseline
Rt-PA and Eptifibatide5051
Rt-PA Only916

[back to top]

Number of Participants With Elevation of Cardiac Enzyme

Number of participants with peri-procedural biomarker elevation defined as any elevation above baseline of CK-MB or Tn-I within 24 hours after completion of the procedure. (NCT01103440)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Conventional Strategy4
Aggressive Strategy2

[back to top]

Number of Participants With Major Adverse Cardiac Event (MACE)

Number of participants with MACE which is any event of Death, MI, Stent Thrombosis, Urgent Revascularization, Bleeding. Major adverse cardiac events (MACE), defined as the composite of death, MI (CK-MB > 3 times normal), urgent revascularization and definite or probable stent thrombosis (ST) within 30 days. Stent thrombosis was defined according to the new academic research consortium definitions; 2) bleeding complications within 30 days. Major bleeding was defined as intracranial or intraocular bleeding or a drop in hemoglobin > 5 g/dL. Minor bleeding was defined as hemorrhage at the access site requiring intervention, hematoma with a diameter of at least 5 cm, a reduction in hemoglobin levels of at least 4 g/dL without an overt bleeding source or at least 3 g/dL with such a source, reoperation for bleeding or transfusion of a blood product. (NCT01103440)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Conventional Strategy5
Aggressive Strategy1

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (≥ 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 10 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)36
Eptifibatide (Integrilin)35
Long Tirofiban (Aggrastat)32

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)69
Eptifibatide (Integrilin)60
Long Tirofiban (Aggrastat)48

[back to top]

Individual Components of Death, Urgent Target Revascularization or Major Bleeding

Individual components of death (any-cause), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 major bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

,,
InterventionParticipants (Count of Participants)
DeathuTVRREPLACE-2 Major Bleeding
Eptifibatide (Integrilin)101
Long Tirofiban (Aggrastat)014
Short Tirofiban (Aggrastat)010

[back to top]

Individual Components of Periprocedural Myonecrosis

Individual components of periprocedural myonecrosis (PPM) (defined as ≥ 3 times, ≥ 10 times, ≥ 20 times or ≥ 50 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value) (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

,,
InterventionParticipants (Count of Participants)
≥ 3 times ULN≥ 10 times ULN≥ 20 times ULN≥ 50 times ULN
Eptifibatide (Integrilin)60352719
Long Tirofiban (Aggrastat)4528219
Short Tirofiban (Aggrastat)69361911

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), or urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)69
Eptifibatide (Integrilin)60
Long Tirofiban (Aggrastat)45

[back to top]

Major Adverse Cardiac and Cerebrovascular Events (MACCE)

MACCE was defined as combined death, nonfatal myocardial infarction, cerebrovascular event (stroke) and the need for re-hospitalization due to recurrent ischemia up to 12 months follow-up (NCT01863134)
Timeframe: Up to 12 month

InterventionPercentage of study group (Number)
Placebo35.3
Eptifibatide13.8

[back to top]

Bleeding Complications

Number of subjects that developed gastrointestinal bleeding after Percutaneous Coronary Intervention (PCI). These subjects were categorized under Bleeding Academic Research Consortium 3b. Type 3b bleeding includes overt bleeding plus a hemoglobin drop of ≥5 g/dL (provided the hemoglobin drop is related to bleeding), cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid), and bleeding requiring intravenous vasoactive drugs. (NCT01919723)
Timeframe: up to 24 hours

InterventionNumber of subjects (Number)
Ticagrelor and Eptifibatide Bolus0
Ticagrelor & Eptifibatide Bolus+Infusion1

[back to top]

Change in Percent Inhibition of Platelet Aggregation (%IPA)

Change from baseline in %IPA at 2 hours after stimulation with 20µM ADP (µM-micromolar, ADP-Adenosine diphosphate), measured in blood by an aggregometer among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide. (NCT01919723)
Timeframe: Baseline and 2 hours

Interventionpercentage of IPA (Mean)
Ticagrelor and Eptifibatide Bolus99.59
Ticagrelor & Eptifibatide Bolus+Infusion99.88

[back to top]

Periprocedural Myocardial Infarction (PMI)

Number of subjects that developed PMI. Periprocedural myocardial infarction (PMI) was defined as an increase in troponin I values >5 x 99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values >20% after PCI if the baseline value was elevated. (NCT01919723)
Timeframe: Up to 24 hours

InterventionNumber of subjects (Number)
Ticagrelor and Eptifibatide Bolus9
Ticagrelor & Eptifibatide Bolus+Infusion7

[back to top]

High On-treatment Platelet Reactivity (HPR)

Percentage of participants with HPR. HPR is defined as platelet aggregation >59% in response to 20 µM ADP. (NCT01919723)
Timeframe: Comparing baseline and follow-up (2 hours)

,
Interventionpercentage of participants (Number)
Baseline2 h
Ticagrelor & Eptifibatide Bolus+Infusion790
Ticagrelor and Eptifibatide Bolus890

[back to top]

The Number of Participants With Good Outcomes According to the Modified Rankin Score.

Modified Rankin score (mRS) dichotomized to good outcome (mRS 0-1 or return to baseline), poor outcome (all others including death). Results reported are good outcome. (NCT01977456)
Timeframe: 90 days from the date of stroke onset

Interventionparticipants (Number)
Eptifibatide17

[back to top]

The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).

Any parenchymal hemorrhage types PH-1 or PH-2 as visualized on CT (NCT01977456)
Timeframe: within 36 hours after stroke onset

Interventionparticipants (Number)
Eptifibatide1

[back to top]

The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).

Any ICH symptomatic (as defined above) or asymptomatic (that visualized on CT or MRI only) (NCT01977456)
Timeframe: within 36 hours after stroke onset

Interventionparticipants (Number)
Eptifibatide2

[back to top]

The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).

Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator (NCT01977456)
Timeframe: within 36 hours after stroke onset

Interventionparticipants (Number)
Eptifibatide1

[back to top]

Number of Patients With Major Bleeding Complications

We evaluated the number of patients with major bleeding complications. Major bleeding, based on Bleeding Academic Research Consortium (BARC), was defined as type 3a, bleeding + hemoglobin drop of 3 to <5 g/dL; type 3b, bleeding + hemoglobin drop ≥5 g/dL; and type C, intracranial hemorrhage. (NCT02925923)
Timeframe: At 1 year post-PCI

InterventionParticipants (Count of Participants)
Ticagrelor0
Eptifibatide Bolus+Clopidogrel0

[back to top]

Number of Participants With a Periprocedural Myocardial Infarction and Injury (PMI)

The rate of PMI will be compared in patients randomized to crushed ticagrelor vs. eptifibatide bolus +clopidogrel (NCT02925923)
Timeframe: At baseline and every 8 hours post- PCI

InterventionParticipants (Count of Participants)
Ticagrelor24
Eptifibatide Bolus+Clopidogrel14

[back to top]

Heparin Dose, Unit/Kg

For the heparin dose range for the two groups would have a minimum dose of 4693 and a maximum dose of 11141 units per kilogram.The higher the number is indicative that a higher dose of heparin is needed based on kilogram weight. (NCT02925923)
Timeframe: 24 hours after the PCI

Interventionunits per kilogram (Mean)
Ticagrelor8854
Eptifibatide Bolus+Clopidogrel6021

[back to top]

Activated Clotting Time (ACT), Seconds

The Level of the highest ACT during PCI will be compared between the groups (NCT02925923)
Timeframe: At the end of PCI

Interventions (Mean)
Ticagrelor332
Eptifibatide Bolus+Clopidogrel278

[back to top]

Platelet Aggregation Levels

The rates of platelet aggregation with ADP and TRAP will be measured in patients randomized to crushed ticagrelor vs. eptifibatide bolus+clopidogrel (NCT02925923)
Timeframe: At baseline and at 0.5, 2, 4, and 24 hours after loading dose

,
Interventionμmol/L (Mean)
Baseline (ADP 20)0.5 h (ADP 20)2 h (ADP 20)4 h (ADP 20)24 h (ADP 20)Baseline (ADP 5)0.5 h (ADP 5)2 h (ADP 5)4 h (ADP 5)24 h (ADP 5)Baseline (TRAP 20)0.5 h (TRAP 20)2 h (TRAP 20)4 h (TRAP 20)24 h (TRAP 20)Baseline (TRAP 10)0.5 h (TRAP 10)2 h (TRAP 10)
Eptifibatide Bolus+Clopidogrel621.3.343.538541.18.31.627673.961451541.181.57
Ticagrelor655335232556442415186860514854564837

[back to top]

Number of Patients With Negative Clinical Outcomes

The rates of death, myocardial infarction, and revascularization at 1-year post-PCI. (NCT02925923)
Timeframe: At 1-year post-PCI

,
InterventionParticipants (Count of Participants)
DeathMyocardial infarctionRevascularization
Eptifibatide Bolus+Clopidogrel000
Ticagrelor201

[back to top]

Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR)

We assessed platelet aggregation at baseline and during PCI by light transmission aggregomerty. The primary efficacy measure was HPR defined as platelet aggregation >59% at 2 h measured by the Chronlog aggregometer after stimulation with ADP 20 µM. (NCT02925923)
Timeframe: 5 times (at baseline, and at 0.5, 2, 4, and 24 hours after loading dose)

,
Interventioncount of participants (Number)
Baseline (n-50, n-48)0.5 h (n-50, n-48)2 h (n-50, n-48)4 h (n-50, n-48)24 h (n-50, n-48)
Eptifibatide Bolus+Clopidogrel330005
Ticagrelor3724602

[back to top]

Change in Hemoglobin Levels (g/dL)

Hemoglobin levels (g/dL) will be measured at baseline and on the next day after PCI. (NCT02925923)
Timeframe: At baseline and at 24 hours post-PCI

,
Interventiong/dL (Mean)
Baseline (hemoglobin, g/dL)Post-PCI (hemoglobin, g/dL)
Eptifibatide Bolus+Clopidogrel13.3412.71
Ticagrelor13.5212.73

[back to top]

Number of Patients With Minor Bleeding Complications

We evaluated the number of patients with minor bleeding complications. Minor bleeding, based on Bleeding Academic Research Consortium (BARC), was defined as clinically overt (including imaging), resulting in hemoglobin drop of 3 to <5 g/dL. (NCT02925923)
Timeframe: At 24 hours post-PCI

InterventionParticipants (Count of Participants)
Ticagrelor0
Eptifibatide Bolus+Clopidogrel0

[back to top]

Number of Patients With Minor Bleeding Complications

We evaluated the number of patients with minor bleeding complications. Minor bleeding, based on Bleeding Academic Research Consortium (BARC), was defined as clinically overt (including imaging), resulting in hemoglobin drop of 3 to <5 g/dL. (NCT02925923)
Timeframe: At 1 year post-PCI

InterventionParticipants (Count of Participants)
Ticagrelor0
Eptifibatide Bolus+Clopidogrel0

[back to top]

Number of Patients With Major Bleeding Complications

We evaluated the number of patients with major bleeding complications. Major bleeding, based on Bleeding Academic Research Consortium (BARC), was defined as type 3a, bleeding + hemoglobin drop of 3 to <5 g/dL; type 3b, bleeding + hemoglobin drop ≥5 g/dL; and type C, intracranial hemorrhage. (NCT02925923)
Timeframe: At 24 hours post-PCI

InterventionParticipants (Count of Participants)
Ticagrelor0
Eptifibatide Bolus+Clopidogrel0

[back to top]

A Change in Hematocrit Levels

Hematocrit levels (%) will be measured at baseline and on the next day after PCI. (NCT02925923)
Timeframe: At baseline and at 24 hours post-PCI

,
Interventionhematocrit (%) (Mean)
Baseline (hematocrit, %)Post-PCI (hematocrit, %)
Eptifibatide Bolus+Clopidogrel40.0237.5
Ticagrelor40.1137.68

[back to top]